Article Sidebar
Published:
Jul 4, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Benefits afforded by combined temozolomide, radiation and stem cell strategy for glioma therapy
Abstract
Purpose: To compare the efficacy of temozolomide, radiation and stem cell therapy in glioma management.
Methods: A total of 112 patients with glioblastoma were divided into four groups, each of 28 patients. Group I received daily temozolomide at 150 mg/m2; Group II radiotherapy of 30.0 Gy; Group III mesenchymal stem cells only; and Group IV all three treatments (temozolomide 100 mg/m2 + 30.0 Gy of radiotherapy + two infusions of mesenchymal stem cells, weekly for 3 weeks. All patients were assessed 1, 6, and 12 months following the conclusion of treatment.
Results: Of Group I patients, the maximum improvement in tumor diameter was 58 % but only 28 % ultimately survived. Of Group II patients, the maximum improvement was 49 % but, again, only 28 % survived (p = 0.06 for both groups). Of Group III patients, the maximum improvement was 71 % and 40% survived. Of Group IV patients, who received all three treatments, the maximum improvement was 80%. The survival rate was 60 %.
Conclusion: Stem cells improved patient outcomes and may be a useful alternative therapy for glioma.
Keywords: Glioma therapy, Temozolomide, Stem cells, Prognosis, Radiotherapy
